Skip to Content

Hydralazine Hydrochloride

Class: Direct Vasodilators
VA Class: CV490
CAS Number: 304-20-1

Medically reviewed by Drugs.com. Last updated on Apr 1, 2019.

Introduction

Vasodilating agent.134 e

Uses for Hydralazine Hydrochloride

Hypertension

Management of hypertension (alone or in combination with other classes of antihypertensive agents).134

Not considered a preferred agent for initial management of hypertension according to current guidelines for the management of hypertension in adults, but may be used as add-on therapy if BP not adequately controlled with the recommended antihypertensive drug classes (i.e., ACE inhibitors, angiotensin II receptor antagonists, calcium-channel blockers, thiazide diuretics).501 502 503 504 1200

Individualize choice of therapy; consider patient characteristics (e.g., age, ethnicity/race, comorbidities, cardiovascular risk) as well as drug-related factors (e.g., ease of administration, availability, adverse effects, cost).501 502 503 504 515 1200 1201

A 2017 ACC/AHA multidisciplinary hypertension guideline classifies BP in adults into 4 categories: normal, elevated, stage 1 hypertension, and stage 2 hypertension.1200 (See Table 1.)

Source: Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13-115.

Individuals with SBP and DBP in 2 different categories (e.g., elevated SBP and normal DBP) should be designated as being in the higher BP category (i.e., elevated BP).

Table 1. ACC/AHA BP Classification in Adults1200

Category

SBP (mm Hg)

DBP (mm Hg)

Normal

<120

and

<80

Elevated

120–129

and

<80

Hypertension, Stage 1

130–139

or

80–89

Hypertension, Stage 2

≥140

or

≥90

The goal of hypertension management and prevention is to achieve and maintain optimal control of BP.1200 However, the BP thresholds used to define hypertension, the optimum BP threshold at which to initiate antihypertensive drug therapy, and the ideal target BP values remain controversial.501 503 504 505 506 507 508 515 523 526 530 1200 1201 1207 1209 1222 1223 1229

The 2017 ACC/AHA hypertension guideline generally recommends a target BP goal (i.e., BP to achieve with drug therapy and/or nonpharmacologic intervention) of <130/80 mm Hg in all adults regardless of comorbidities or level of atherosclerotic cardiovascular disease (ASCVD) risk.1200 In addition, an SBP goal of <130 mm Hg generally is recommended for noninstitutionalized ambulatory patients ≥65 years of age with an average SBP of ≥130 mm Hg.1200 These BP goals are based upon clinical studies demonstrating continuing reduction of cardiovascular risk at progressively lower levels of SBP.1200 1202 1210

Other hypertension guidelines generally have based target BP goals on age and comorbidities.501 504 536 Guidelines such as those issued by the JNC 8 expert panel generally have targeted a BP goal of <140/90 mm Hg regardless of cardiovascular risk, and have used higher BP thresholds and target BPs in elderly patients501 504 536 compared with those recommended by the 2017 ACC/AHA hypertension guideline.1200

Some clinicians continue to support previous target BPs recommended by JNC 8 due to concerns about the lack of generalizability of data from some clinical trials (e.g., SPRINT study) used to support the 2017 ACC/AHA hypertension guideline and potential harms (e.g., adverse drug effects, costs of therapy) versus benefits of BP lowering in patients at lower risk of cardiovascular disease.1222 1223 1224 1229

Consider potential benefits of hypertension management and drug cost, adverse effects, and risks associated with the use of multiple antihypertensive drugs when deciding a patient's BP treatment goal.1200 1220

For decisions regarding when to initiate drug therapy (BP threshold), the 2017 ACC/AHA hypertension guideline incorporates underlying cardiovascular risk factors.1200 1207 ASCVD risk assessment is recommended by ACC/AHA for all adults with hypertension.1200

ACC/AHA currently recommend initiation of antihypertensive drug therapy in addition to lifestyle/behavioral modifications at an SBP ≥140 mm Hg or DBP ≥90 mm Hg in adults who have no history of cardiovascular disease (i.e., primary prevention) and a low ASCVD risk (10-year risk <10%).1200

For secondary prevention in adults with known cardiovascular disease or for primary prevention in those at higher risk for ASCVD (10-year risk ≥10%), ACC/AHA recommend initiation of antihypertensive drug therapy at an average SBP ≥130 mm Hg or an average DBP ≥80 mm Hg.1200

Adults with hypertension and diabetes mellitus, chronic kidney disease (CKD), or age ≥65 years are assumed to be at high risk for cardiovascular disease; ACC/AHA state that such patients should have antihypertensive drug therapy initiated at a BP ≥130/80 mm Hg.1200 Individualize drug therapy in patients with hypertension and underlying cardiovascular or other risk factors.502 1200

In stage 1 hypertension, experts state that it is reasonable to initiate drug therapy using the stepped-care approach in which one drug is initiated and titrated and other drugs are added sequentially to achieve the target BP.1200 Consider initiation of antihypertensive therapy with 2 first-line agents from different pharmacologic classes in adults with stage 2 hypertension and average BP >20/10 mm Hg above BP goal.1200

Severe Hypertension and Hypertensive Crises

One of several recommended parenteral agents for use in the hospital setting to urgently lower BP in severely hypertensive pregnant women, including those with preeclampsia.112 139 540 1200

Historically considered the agent of choice for management of hypertensive emergencies associated with pregnancy (e.g., preeclampsia, eclampsia);542 however, some clinicians prefer IV labetalol for its more rapid onset, shorter duration of action, and more predictable hypotensive effect.502 542

Parenteral management of severe hypertension when the drug cannot be given orally or when BP must be lowered immediately;e other parenteral antihypertensive agents (e.g., labetalol, esmolol, fenoldopam, nicardipine, sodium nitroprusside) usually are preferred for these indications.502 542 1200 b

Not recommended for the management of severe hypertension or hypertensive emergencies associated with cerebrovascular accidents or in patients with cerebral edema and encephalopathy.b

Heart Failure

Used in fixed combination with isosorbide dinitrate as adjunct to standard therapy for the treatment of heart failure in self-identified black patients to improve survival, decrease rate of hospitalization for worsened heart failure, and improve patient-reported functional status.135 136 137

Current guidelines recommend a combination of drug therapies (e.g., ACE inhibitors, angiotensin II receptor antagonists, angiotensin receptor-neprilysin inhibitors [ARNIs], β-adrenergic blocking agents [β-blockers], aldosterone receptor antagonists) in adults with heart failure to reduce morbidity and mortality.524 701 703 800

Combination of hydralazine and isosorbide dinitrate recommended by ACCF and AHA for self-identified black patients with NYHA class III or IV heart failure and reduced ejection fraction who are receiving optimal therapy with ACE inhibitors and β-blockers, unless contraindicated.524

ACCF and AHA state that combined therapy with hydralazine and isosorbide dinitrate also can be useful in patients with current or prior symptomatic heart failure with reduced ejection fraction who cannot receive an ACE inhibitor or angiotensin II receptor antagonist because of drug intolerance, hypotension, or renal insufficiency.524

Hydralazine Hydrochloride Dosage and Administration

General

BP Monitoring and Treatment Goals

  • Monitor BP regularly (i.e., monthly) during therapy and adjust dosage of the antihypertensive drug until BP controlled.1200

  • If unacceptable adverse effects occur, discontinue drug and initiate another antihypertensive agent from a different pharmacologic class.1216

  • If adequate BP response not achieved with a single antihypertensive agent, either increase dosage of single drug or add a second drug with demonstrated benefit and preferably a complementary mechanism of action (e.g., ACE inhibitor, angiotensin II receptor antagonist, calcium-channel blocker, thiazide diuretic).1200 1216 Many patients will require ≥2 drugs from different pharmacologic classes to achieve BP goal; if goal BP still not achieved with 2 antihypertensive agents, add a third drug.1200 1216 1220

Hypertensive Crises

  • Monitor BP closely when parenteral hydralazine is used.e

  • Avoid abrupt discontinuance in patients with a marked reduction in BP.109 To minimize risk for sudden BP increase, reduce dosage gradually.b

  • Adults with a hypertensive emergency and a compelling indication—pheochromocytoma crisis, severe preeclampsia or eclampsia: Reduce SBP to <140 mm Hg within the first hour.1200

  • Adults with a hypertensive emergency and a compelling indication—acute aortic dissection: Reduce SBP to <120 mm Hg within the first 20 minutes.1200

  • Children and adolescents: Some experts suggest reducing BP by ≤25% of the planned reduction over the first 8 hours, with remainder of planned reduction over next 12–24 hours.1150

  • Initial goal of IV therapy in adults without a compelling indication is to reduce systolic BP by ≤25% within the first hour, followed by further reduction if stable to 160/110 or 160/100 mm Hg within the next 2–6 hours, avoiding excessive declines in pressure that could precipitate renal, cerebral, or coronary ischemia.1200 If this BP is well tolerated and the patient is clinically stable, further gradual reductions toward normal BP can be implemented in the next 24–48 hours.1200

Administration

Administer orally or by IM or IV injection.b Usually administer orally; may be administered IM or IV if patient unable to take drug orally or if a rapid decrease in BP is required.b

Oral Administration

Administer orally 2–4 times daily.134 b

IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

Administer by rapid IV injection directly into the vein.e

Replace parenteral therapy with oral therapy as soon as possible.b

Dosage

Available as hydralazine hydrochloride; dosage expressed in terms of the salt.b

20–25 mg of IV hydralazine hydrochloride was approximately equal to 75–100 mg of oral hydralazine hydrochloride in one study.b

Pediatric Patients

Hypertension
Oral

Some clinicians recommend an initial dosage of 0.75 mg/kg daily given in 4 divided doses.601

Dosages may be increased gradually (over 3–4 weeks) up to a maximum of 7.5 mg/kg (or 200 mg) daily.601

Severe Hypertension
IM or IV

Usual dosage: Manufacturer states that 1.7–3.5 mg/kg daily given in 4–6 divided doses has been used.600

Severe Hypertension with Life-Threatening Symptoms
IV or IM

Some experts recommend initial dosage of 0.1–0.2 mg/kg per dose.1150 May increase dosage up to 0.4 mg/kg per dose.1150 May administer every 4 hours when given by direct IV (“bolus”) injection.1150

Severe Hypertension with Non-Life-Threatening Symptoms
Oral

0.25 mg/kg per dose up to 25 mg per dose; administer every 6–8 hours.1150

Adults

Hypertension
Oral

Initially, 10 mg 4 times daily for 2–4 days.134 Dosage then can be increased to 25 mg 4 times daily for the remainder of the week.134 If necessary, dosage can be increased for the second and subsequent weeks to 50 mg 4 times daily.134

Some experts recommend usual dosage of 100–200 mg daily, administered in 2 or 3 divided doses.1200

Severe Hypertension/Hypertensive Crises
IV

Usual dose: Manufacturer states 20–40 mg, repeated as necessary; can transfer most patients to oral therapy within 24–28 hours.600

Alternatively, some experts recommend 10–20 mg repeated every 4–6 hours as needed.1200

IM

Usual dose: Manufacturer states 20–40 mg, repeated as necessary; can transfer most patients to oral therapy within 24–28 hours.600

Urgent Reduction of BP during Pregnancy
IV

Usual initial dose is 5 mg,101 103 105 108 112 540 followed by 5–10 mg every 20–40 minutes as necessary to achieve an adequate BP reduction.101 102 103 104 105 108 112 540 Maximum total dose of 20 mg has been recommended.540

Heart Failure
Fixed-combination Therapy with Isosorbide Dinitrate in Self-identified Black Patients
Oral

Initially, hydralazine hydrochloride 37.5 mg and isosorbide dinitrate 20 mg (1 tablet of BiDil) 3 times daily.135 524 May titrate dosage to a maximum tolerated dosage not to exceed 2 tablets (a total of 75 mg of hydralazine hydrochloride and 40 mg of isosorbide dinitrate) 3 times daily.135 524 Rapid titration (over 3–5 days) may be possible; however, slower titration may be needed due to adverse effects.135 May decrease dosage to as little as one-half of the fixed-combination tablet 3 times daily in patients who experience intolerable effects, but attempt to titrate dosage up once adverse effects subside.135

Hydralazine Therapy
Oral

ACCF and AHA recommend initial dosage of hydralazine hydrochloride 25–50 mg 3 or 4 times daily; give concomitantly with isosorbide dinitrate 20–30 mg 3 or 4 times daily.524 Titrate dosages to levels similar to those recommended for the fixed-combination preparation and administer both drugs at least 3 times daily.524

Prescribing Limits

Pediatric Patients

Hypertension
Oral

Maximum 7.5 mg/kg daily (or 200 mg daily).601

Adults

Heart Failure
Fixed-combination Therapy with Isosorbide Dinitrate in Self-identified Black Patients
Oral

Maximum 75 mg of hydralazine hydrochloride and 40 mg of isosorbide dinitrate (2 tablets of BiDil) 3 times daily.135

Hydralazine Therapy
Oral

Maximum 300 mg daily administered concomitantly with isosorbide dinitrate (maximum 120 mg daily).524

Special Populations

Renal Impairment

Lower dosage may be required in severe renal failure.b

Geriatric Patients

The manufacturer of the fixed combination of hydralazine hydrochloride and isosorbide dinitrate states that dosage should be selected with caution because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.135

Cautions for Hydralazine Hydrochloride

Contraindications

  • CAD.134 e

  • Mitral valvular rheumatic heart disease.134 e

  • Hypersensitivity to hydralazine hydrochloride or any ingredient in the formulation.134 e

Warnings/Precautions

Warnings

Systemic Lupus Erythematosus (SLE)

May cause SLE (e.g., glomerulonephritis) or rheumatoid arthritis,134 e particularly in patients receiving >200 mg daily dosage for prolonged periods, in slow acetylators of hydralazine, or in those with decreased renal function.b

If unexplained signs and symptoms (e.g., arthralgia, fever, chest pain, continued malaise) occur, perform appropriate laboratory studies (e.g., CBCs, ANA titer determinations).b

If test results confirm SLE, discontinue hydralazine unless benefit outweighs risk.b Signs and symptoms usually regress with hydralazine discontinuance, but residual effects may be detected after many years.134 b Long-term corticosteroid treatment may be necessary if symptoms do not regress.b

Sensitivity Reactions

Sulfite Sensitivity

Some formulations contain sulfites that may cause allergic-type reactions (including anaphylaxis and life-threatening or less severe asthmatic episodes) in certain susceptible individuals.b

General Precautions

Cardiovascular Effects

Possible precipitation of angina attacks and/or MI; 134 b use with caution in patients with suspected coronary artery disease.134 e

May increase pulmonary artery pressure in patients with mitral valvular disease.134 e (See Contraindications.)

Possible orthostatic hypotension; use with caution in patients with cerebrovascular accidents,134 135 those who may be volume-depleted, those with preexisting hypotension, or those receiving other hypotensive agents.135 b

Drug Interaction

May paradoxically reduce pressor response to epinephrine.134 b

Peripheral Neuritis

Possible peripheral neuritis (e.g., paresthesia, numbness, tingling);134 e may be caused by pyridoxine deficiency.b

If such symptoms occur, use concomitantly with pyridoxine.b

Hematologic Effects

Possible blood dyscrasias (e.g., decreased hemoglobin and erythrocytes, leukopenia, agranulocytosis, thrombocytopenia with or without purpura).134 e

If such abnormalities occur, discontinue therapy.134 e

Adequate Patient Monitoring

Perform CBCs and ANA titer determinations before initiation and then periodically thereafter during prolonged therapy (even in asymptomatic patients).134 b e

Manufacturers state that a positive ANA titer requires that the implications of the test result be weighed against the benefits from therapy with the drug,134 e whereas some experts state that an increase in ANA titer requires immediate discontinuance of the drug.b

Carefully monitor hemodynamic and clinical status in patients with acute MI.135

Use of Fixed Combinations

When hydralazine is used in fixed combination with isosorbide dinitrate, consider the cautions, precautions, and contraindications associated with isosorbide dinitrate.135

Specific Populations

Pregnancy

Category C.134 e

Lactation

Distributed into milk.b Use caution.134 e

Pediatric Use

Safety and efficacy alone or in fixed combination with isosorbide dinitrate not established.134 135 e Use is based on clinical experience.134 e

Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.135 (See Geriatric Patients under Dosage.)

Renal Impairment

Generally considered to be safe; manufacturers state to use with caution in severe renal impairment.b

Common Adverse Effects

Headache, palpitation, tachycardia.b

Interactions for Hydralazine Hydrochloride

Specific Drugs

Drug

Interaction

Comments

β-Blockers

Additive hypotensive effectb

Concomitant use may minimize adverse cardiac effects (e.g., tachycardia, precipitation of angina) associated with hydralazineb

Usually used to therapeutic advantage; adjust dosages carefully and monitor for excessive BP reductionb

Diazoxide, IV (no longer commercially available in US)

Possibly profound hypotensive episodesb

Diuretics

Additive hypotensive effectb

Concomitant use may prevent tolerance to hydralazine and also prevent sodium retention and increased plasma volume that may occur after prolonged hydralazine therapyb

Usually used to therapeutic advantage; adjust dosage carefully and monitor for excessive BP reductionb

Epinephrine

Decreased pressor response to epinephrine134 e

Hypotensive agents

Additive hypotensive effectb

Usually used to therapeutic advantage; adjust dosage carefully and monitor for excessive BP reductionb

MAO inhibitors

Synergistic effect, resulting in marked BP decreaseb

Use concomitantly with cautionb

Phosphodiesterase (PDE) inhibitors, selective when using hydralazine in fixed combination with isosorbide dinitrate

Sildenafil and other selective PDE inhibitors (e.g., tadalafil, vardenafil) profoundly potentiate the vasodilatory effects of isosorbide dinitrate and potentially life-threatening hypotension and/or hemodynamic compromise can result135

Because of the serious risk of concurrent use of isosorbide dinitrate and selective PDE inhibitors, such combined use is contraindicated135

Hydralazine Hydrochloride Pharmacokinetics

Absorption

Bioavailability

Absorption from GI tract is rapid;b 66% of an oral dose may be absorbed.135

Onset

Following oral administration, antihypertensive effect occurs in 20–30 minutes.b

Following IM administration, hypotensive effect occurs within 10–30 minutes.b

Following IV administration, hypotensive effect occurs within 5–20 minutes, is maximum in 10–80 minutes.b

Duration

Following oral administration, antihypertensive effect lasts 2–4 hours.b

Following IM administration, hypotensive effect lasts 2–6 hours.b

Following IV administration, hypotensive effect lasts 2–6 hours.b

Food

Food increases plasma hydralazine concentrations.134 The effect of food on the bioavailability of hydralazine when administered in fixed combination with isosorbide dinitrate is not known.135

Distribution

Extent

Widely distributed into body tissues in animals;b highest concentrations in kidneys, plasma, and liver; high affinity for arterial walls;b lower concentrations in the brain, lungs, muscle, heart, and fat.b

Readily crosses the placenta.b

Distributed into milk.b

Plasma Protein Binding

85–87%.b

Elimination

Metabolism

Metabolized extensively in the GI mucosa during absorption and in the liver by acetylation, hydroxylation, and conjugation with glucuronic acid.b

Acetylation rate is genetically determined; slow acetylators have higher plasma hydralazine concentrations than rapid acetylators at the same oral dose.b

Elimination Route

Excreted principally in urine as metabolites and in feces (10%).b

Half-life

Plasma half-life: approximately 2–4 hours.b

Special Populations

Not known whether hydralazine is dialyzable.b

Not known whether impaired renal or hepatic function has an effect on the pharmacokinetics of hydralazine.135

Hydralazine may be eliminated more slowly in geriatric patients.135

Stability

Storage

Oral

Tablets

Tight, light-resistant containers at 15–30°C.134 b

Tablets (Hydralazine Hydrochloride and Isosorbide Dinitrate)

Tight, light-resistant containers at 25°C (may be exposed to 15–30°C).135

Parenteral

Injection

15–30°;e avoid freezing.b

Compatibility

For information on systemic interactions resulting from concomitant use, see Interactions.

Parenteral

Color change develops after dilution with most IV infusion solutions.b Color changes that occur over 8–12 hours generally do not indicate loss of potency when stored at ≤30°C.b

Solution CompatibilityHID

Compatible

Dextrose–Ringer’s injection combinations

Dextrose 5% in Ringer’s injection, lactated

Dextrose 2.5% in half-strength Ringer’s injection, lactated

Dextrose–saline combinations

Dextrose 2.5 or 10% in water

Ionosol products

Ringer’s injection

Ringer’s injection, lactated

Sodium chloride 0.45 or 0.9%

Sodium lactate 1/6 M

Incompatible

Dextrose 5% in water

Dextrose 10% in Ringer’s injection, lactated

Drug Compatibility
Admixture CompatibilityHID

Compatible

Dobutamine HCl

Incompatible

Aminophylline

Ampicillin sodium

Chlorothiazide sodium

Edetate calcium disodium

Ethacrynate sodium

Hydrocortisone sodium succinate

Methohexital sodium

Nitroglycerin

Phenobarbital sodium

Verapamil HCl

Y-Site CompatibilityHID

Compatible

Caspofungin acetate

Heparin sodium

Hydrocortisone sodium succinate

Potassium chloride

Verapamil HCl

Incompatible

Aminophylline

Ampicillin sodium

Furosemide

Nesiritide

Variable

Nitroglycerin

Actions

  • Mechanism of action as an antihypertensive agent is presumed to be a result of a direct vasodilatory effect on vascular smooth muscle.134 e

Advice to Patients

  • Importance of informing clinician about occurrence of SLE symptoms (e.g., joint or chest pain or fever).134 e

  • Potential to impair mental alertness or physical coordination; avoid driving or operating machinery until effects on individual are known.134 e

  • Importance of consulting clinician if headache continues with repeated dosing.135

  • Importance of informing patients receiving hydralazine in fixed combination with isosorbide dinitrate that inadequate fluid intake or excessive fluid loss due to diarrhea, vomiting, or perspiration may result in excessive hypotension, possibly leading to lightheadedness or syncope; if syncope occurs, discontinue treatment and notify clinician immediately.135

  • Importance of taking hydralazine regularly and continuously as prescribed.134 e

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.134 e

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.134 e

  • Importance of informing patients of other important precautionary information.134 e (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

hydrALAZINE Hydrochloride

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets

10 mg*

Hydralazine Hydrochloride Tablets

25 mg*

Hydralazine Hydrochloride Tablets

50 mg*

Hydralazine Hydrochloride Tablets

100 mg*

Hydralazine Hydrochloride Tablets

Parenteral

Injection

20 mg/mL*

Hydralazine Hydrochloride Injection

hydrALAZINE Hydrochloride Combinations

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets, film-coated

37.5 mg with Isosorbide Dinitrate 20 mg

BiDil (scored)

NitroMed

AHFS DI Essentials™. © Copyright 2019, Selected Revisions April 1, 2019. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

Only references cited for selected revisions after 1984 are available electronically.

101. Pritchard J, Stone SR. Clinical and laboratory observations on eclampsia. Am J Obstet Gynecol. 1967; 99:754-65. http://www.ncbi.nlm.nih.gov/pubmed/5301234?dopt=AbstractPlus

102. Pritchard JA, Pritchard SA. Standardized treatment of 154 consecutive cases of eclampsia. Am J Obstet Gynecol. 1975; 123:543-51. http://www.ncbi.nlm.nih.gov/pubmed/1180300?dopt=AbstractPlus

103. Nissen JC. Treatment of hypertensive emergencies of pregnancy. Clin Pharm. 1982; 1:334-43. http://www.ncbi.nlm.nih.gov/pubmed/6764393?dopt=AbstractPlus

104. Lubbe WF. Hypertension in pregnancy: pathophysiology and management. Drugs. 1984; 28:170-88. http://www.ncbi.nlm.nih.gov/pubmed/6147240?dopt=AbstractPlus

105. Lindheimer MD, Katz AI. Current concepts: hypertension in pregnancy. N Engl J Med. 1985; 313:675-80. http://www.ncbi.nlm.nih.gov/pubmed/3894964?dopt=AbstractPlus

108. National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group report on high blood pressure in pregnancy. Am J Obstet Gynecol. 1990; 163:1689-1712.

109. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Bethesda, MD: National Institutes of Health; 1997 Nov. (NIH publication No. 98-4080.)

110. Kaplan NM. Choice of initial therapy for hypertension. JAMA. 1996; 275:1577-80. http://www.ncbi.nlm.nih.gov/pubmed/8622249?dopt=AbstractPlus

111. Rey E, LeLorier J, Burgess E et al. Report of the Canadian Hypertension Society consensus conference: 3. pharmacologic treatment of hypertensive disorders in pregnancy. CMAJ. 1997; 157:1245-54. http://www.ncbi.nlm.nih.gov/pubmed/9361646?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1228354&blobtype=pdf

112. ACOG task force on hypertension in pregnancy: hypertension in pregnancy. Washington, DC: American College of Obstetricians and Gynecologists; 2013.

113. Anon. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Part II. Management of heart failure: approaches to the prevention of heart failure. Am J Cardiol. 1999; 83:9A-38A.

114. Cohn JN, Archibald DG, Ziesche S et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med. 1986; 314:1547-52. http://www.ncbi.nlm.nih.gov/pubmed/3520315?dopt=AbstractPlus

115. Cohn JN, Johnson G, Ziesche et al. A comparison of enalapril with hydralazine—isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991; 325:303-10. http://www.ncbi.nlm.nih.gov/pubmed/2057035?dopt=AbstractPlus

116. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. Hypertension. 2000; 35:1021-4. http://www.ncbi.nlm.nih.gov/pubmed/10818056?dopt=AbstractPlus

117. Frohlich ED. Recognition of systolic hypertension for hypertension. Hypertension. 2000; 35:1019-20. http://www.ncbi.nlm.nih.gov/pubmed/10818055?dopt=AbstractPlus

118. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000; 36:646-61. http://www.ncbi.nlm.nih.gov/pubmed/10977801?dopt=AbstractPlus

119. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998; 351:1755-62. http://www.ncbi.nlm.nih.gov/pubmed/9635947?dopt=AbstractPlus

122. Appel LJ. The verdict from ALLHAT—thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2002; 288:3039-60. http://www.ncbi.nlm.nih.gov/pubmed/12479770?dopt=AbstractPlus

123. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981-97. http://www.ncbi.nlm.nih.gov/pubmed/12479763?dopt=AbstractPlus

124. National High Blood Pressure Education Program.. Report of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy. Am J Obstet Gynecol. 2000; 183:S1-22.

125. Whelton PK, Appel LJ, Espeland MA et al. for the TONE Collaborative Research Group. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA. 1998; 279:839-46. http://www.ncbi.nlm.nih.gov/pubmed/9515998?dopt=AbstractPlus

127. Psaty BM, Smith NL, Siscovick DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA. 1997; 277:739-45. http://www.ncbi.nlm.nih.gov/pubmed/9042847?dopt=AbstractPlus

130. The Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee. 1999 guidelines for the management of hypertension. J Hypertension. 1999; 17:392-403.

132. Carter B for the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Personal communication.

133. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004; 114(Suppl 2):555-76. http://www.ncbi.nlm.nih.gov/pubmed/15286277?dopt=AbstractPlus

134. Par Pharmaceutical, Inc. Hydralazine hydrochloride tablets prescribing information. Spring Valley, NY; 2003 Jun.

135. NitroMed, Inc. BiDil (isosorbide dinitrate and hydralazine hydrochloride) tablets prescribing information. Lexington, MA; 2005 Jun 23.

136. Taylor AL, Ziesche S, Yancy C et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004; 351:2049-57. http://www.ncbi.nlm.nih.gov/pubmed/15533851?dopt=AbstractPlus

137. Anon. BiDil for heart failure. Med Lett Drugs Ther. 2005; 47:77-8.

139. Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2013; 7:CD001449. http://www.ncbi.nlm.nih.gov/pubmed/23857334?dopt=AbstractPlus

501. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311:507-20. http://www.ncbi.nlm.nih.gov/pubmed/24352797?dopt=AbstractPlus

502. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31:1281-357. http://www.ncbi.nlm.nih.gov/pubmed/23817082?dopt=AbstractPlus

503. Go AS, Bauman MA, Coleman King SM et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014; 63:878-85. http://www.ncbi.nlm.nih.gov/pubmed/24243703?dopt=AbstractPlus

504. Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014; 16:14-26. http://www.ncbi.nlm.nih.gov/pubmed/24341872?dopt=AbstractPlus

505. Wright JT, Fine LJ, Lackland DT et al. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014; 160:499-503. http://www.ncbi.nlm.nih.gov/pubmed/24424788?dopt=AbstractPlus

506. Mitka M. Groups spar over new hypertension guidelines. JAMA. 2014; 311:663-4. http://www.ncbi.nlm.nih.gov/pubmed/24549531?dopt=AbstractPlus

507. Peterson ED, Gaziano JM, Greenland P. Recommendations for treating hypertension: what are the right goals and purposes?. JAMA. 2014; 311:474-6. http://www.ncbi.nlm.nih.gov/pubmed/24352710?dopt=AbstractPlus

508. Bauchner H, Fontanarosa PB, Golub RM. Updated guidelines for management of high blood pressure: recommendations, review, and responsibility. JAMA. 2014; 311:477-8. http://www.ncbi.nlm.nih.gov/pubmed/24352759?dopt=AbstractPlus

515. Thomas G, Shishehbor M, Brill D et al. New hypertension guidelines: one size fits most?. Cleve Clin J Med. 2014; 81:178-88. http://www.ncbi.nlm.nih.gov/pubmed/24591473?dopt=AbstractPlus

523. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012; 126:e354-471.

524. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128:e240-327.

526. Kernan WN, Ovbiagele B, Black HR et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014; :. http://www.ncbi.nlm.nih.gov/pubmed/24788967?dopt=AbstractPlus

530. Myers MG, Tobe SW. A Canadian perspective on the Eighth Joint National Committee (JNC 8) hypertension guidelines. J Clin Hypertens (Greenwich). 2014; 16:246-8. http://www.ncbi.nlm.nih.gov/pubmed/24641124?dopt=AbstractPlus

536. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012: 2: 337-414.

540. Magee LA, Pels A, Helewa M et al., for the Canadian Hypertensive Disorders of Pregnancy (HDP) Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens. 2014; 4:105-45. http://www.ncbi.nlm.nih.gov/pubmed/26104418?dopt=AbstractPlus

542. Marik PE, Varon J. Hypertensive crises: challenges and management. Chest. 2007; 131:1949-62. http://www.ncbi.nlm.nih.gov/pubmed/17565029?dopt=AbstractPlus

600. Akorn., Inc. Hydralazine hydrochloride injection prescribing information. Lake Forest, IL; 2016 Jun.

601. Nivagen Pharmaceuticals. Hydralazine hydrochloride tablets prescribing information. Sacramento, CA; 2016 Aug.

701. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; :. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4946749&blobtype=pdf

703. Ansara AJ, Kolanczyk DM, Koehler JM. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck. J Clin Pharm Ther. 2016; 41:119-27. http://www.ncbi.nlm.nih.gov/pubmed/26992459?dopt=AbstractPlus

800. Yancy CW, Jessup M, Bozkurt B et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016; :.

1150. Flynn JT, Kaelber DC, Baker-Smith CM et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017; 140 http://www.ncbi.nlm.nih.gov/pubmed/28827377?dopt=AbstractPlus

1200. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018; 71:el13-e115. http://www.ncbi.nlm.nih.gov/pubmed/29133356?dopt=AbstractPlus

1201. Bakris G, Sorrentino M. Redefining hypertension - assessing the new blood-pressure guidelines. N Engl J Med. 2018; 378:497-499. http://www.ncbi.nlm.nih.gov/pubmed/29341841?dopt=AbstractPlus

1202. Carey RM, Whelton PK, 2017 ACC/AHA Hypertension Guideline Writing Committee. Prevention, detection, evaluation, and management of high blood pressure in adults: synopsis of the 2017 American College of Cardiology/American Heart Association hypertension guideline. Ann Intern Med. 2018; 168:351-358. http://www.ncbi.nlm.nih.gov/pubmed/29357392?dopt=AbstractPlus

1207. Burnier M, Oparil S, Narkiewicz K et al. New 2017 American Heart Association and American College of Cardiology guideline for hypertension in the adults: major paradigm shifts, but will they help to fight against the hypertension disease burden?. Blood Press. 2018; 27:62-65. http://www.ncbi.nlm.nih.gov/pubmed/29447001?dopt=AbstractPlus

1209. Qaseem A, Wilt TJ, Rich R et al. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2017; 166:430-437. http://www.ncbi.nlm.nih.gov/pubmed/28135725?dopt=AbstractPlus

1210. SPRINT Research Group, Wright JT, Williamson JD et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015; 373:2103-16. http://www.ncbi.nlm.nih.gov/pubmed/26551272?dopt=AbstractPlus

1216. Taler SJ. Initial treatment of hypertension. N Engl J Med. 2018; 378:636-644. http://www.ncbi.nlm.nih.gov/pubmed/29443671?dopt=AbstractPlus

1220. Cifu AS, Davis AM. Prevention, detection, evaluation, and management of high blood pressure in adults. JAMA. 2017; 318:2132-2134. http://www.ncbi.nlm.nih.gov/pubmed/29159416?dopt=AbstractPlus

1222. Bell KJL, Doust J, Glasziou P. Incremental benefits and harms of the 2017 American College of Cardiology/American Heart Association high blood pressure guideline. JAMA Intern Med. 2018; 178:755-7. http://www.ncbi.nlm.nih.gov/pubmed/29710197?dopt=AbstractPlus

1223. LeFevre M. ACC/AHA hypertension guideline: what is new? what do we do?. Am Fam Physician. 2018; 97(6):372-3. http://www.ncbi.nlm.nih.gov/pubmed/29671534%20?dopt=AbstractPlus

1224. Brett AS. New hypertension guideline is released. From NEJM Journal Watch website. Accessed 2018 Jun 18. https://www.jwatch.org/na45778/2017/12/28/nejm-journal-watch-general-medicine-year-review-2017

1229. Ioannidis JPA. Diagnosis and treatment of hypertension in the 2017 ACC/AHA guidelines and in the real world. JAMA. 2018; 319(2):115-6. http://www.ncbi.nlm.nih.gov/pubmed/29242891?dopt=AbstractPlus

HID. Trissel LA. Handbook on injectable drugs. 17th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2013:618-20.

b. AHFS drug information 2015. McEvoy GK, ed. Hydralazine. Bethesda, MD: American Society of Health-System Pharmacists; 2015: .

e. American Regent. Hydralazine hydrochloride injection prescribing information. Shirley, NY; 2002 Jun.

Hide